Portfolio of indications

Prophylactic Vaccines

Indication Discovery Preclinical POC Phase I FIH
    Yellow Fever          .

Therapeutic Vaccines

Indication Discovery Preclinical POC Phase I FIH
    Chronic Hepatitis B

Yellow Fever

  • Yellow fever (YF) is caused by the transmission of the yellow fever (YF) virus via the bite of an infected mosquito.

  • YF occurs in most of sub-Saharan Africa and tropical South America, where it is endemic and intermittently epidemic.

  • YF vaccination is required for travelers to certain countries and is recommended for all travelers to areas subject to endemic and epidemic disease (WHO).

  • Annually, and despite the availability of an effective vaccine, an estimated 200 000 cases of yellow fever with ~ 30 000 deaths occur (CDC).

  • No antiviral drugs are available for the treatment of YF, treatment is directed at symptomatic relief or life-saving interventions.

  • AstriVax candidate thermostable YF vaccine is the basis of the PLLAV platform technology and offers in addition the possibility to create dual vaccines.


  • Rabies is a preventable viral disease most often transmitted through the bite or scratch of a rabid animal. The rabies virus infects the central nervous system of mammals, ultimately causing disease in the brain and death.

  • While rabies is a preventable disease (through pre-exposure prophylaxis and/or post-exposure prophylaxis), an estimated 59 000 people die annually from the disease around the world (CDC).

  • AstriVax’ candidate thermostable rabies vaccine offers dual protection (e.g. also YF protection) and does so with fewer doses given than currently available vaccines

Chronic Hepatitis B

  • Hepatitis B is a condition caused by the hepatitis B virus (HBV). The virus can cause both acute and chronic disease.

  • Chronic hepatitis B (CHB) is a major public health problem.

  • WHO estimates that ~ 300 million people are living with chronic hepatitis B infection, with 1.5 million new infections each year and 820 000 deaths per year (mostly from cirrhosis and hepatocellular carcinoma) (WHO).

  • Antiviral therapy is effective in controlling the disease but does typically not allow to cure the infection. Hence life-long antiviral therapy is required.

  • AstriVax’ candidate CHB therapeutic vaccine, that efficiently induces specific CD8+ T-cells is expected to be a promising component in of a combination therapy that may lead to a functional cure.